Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report
2 Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcin...
3 Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patients
4 Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials, New Report from Cancer Research Institute Reveals
5 FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab
6 IL-8 Antibody Active in Tumors After PD-1/L1 Blockade
7 Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer
8 Managing Toxicities Associated With Immune Checkpoint Inhibitors
9 Therapeutic PD-1 cancer vaccine shown to be safe and effective in animal study: First-in-human clinical trial will test vaccine in select cancer patients
10 Addition of SBRT to nivolumab fails to improve outcomes in metastatic head and neck cancer
11 Immune checkpoint inhibitor efficacy against glioblastoma may decrease with dexamethasone
12 Therapeutic PD-1 Cancer Vaccine Shown to be Safe, Effective in Animal Study
13 Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial.
14 Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies
15 Agilent Receives Expanded FDA Approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer
16 Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes
17 PD-L1 IHC 22C3 pharmDx Gets FDA Approval as Companion Diagnostic for Pembrolizumab in Breast Cancer
18 New Diagnostic Method Helps To Predict Which Cancer Patients Will Respond to Immunotherapy
19 Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...
20 A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology
21 Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors
22 Oncolytic Virus Shows Promise in Colon Cancer Treatment
23 Leap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35th Annual Meeting
24 Dexamethasone May Shorten Survival in Patients With Glioblastoma Treated With ICIs
25 Role of HER2-Directed Therapies Rapidly Evolves in Esophageal and Gastric Cancer
26 Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
27 Impact of chemoradiotherapy on the immune-related tumor microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer
28 Merck Halts Phase 3 Trial on Yervoy-Keytruda Combo in Advanced...
29 Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
30 Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006
31 Revisiting the PD-1 pathway
32 PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ?
33 Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma
34 Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
35 Society for Immunotherapy of Cancer 2020: Pushing the Boundaries of Cancer Treatment
36 New protocols, precision approaches ahead for lung cancer
37 Anti–PD-1/PD-L1 Immunotherapies Continue to Impress in Unique Combinations
38 Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
39 Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
40 Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion
41 Immunotherapy in Advanced Lung Cancer
42 PD-1 and PD-L1 Inhibitors Market: Rapid rise in FDA approval of PD-L1 inhibitors have brought this as a highly lucrative segment
43 Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS® Registry.
44 The Evolution Of Biomarker-driven Approaches To Clinical Trials
45 Immutep Announces Expansion of TACTI-002 Collaboration Trial
46 City of Hope Has Developed a Cancer-killing Virus That Activates Immune System, Helps Eliminate Colon Cancer
47 CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
48 Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy
49 Biomarker Identified for Anti–PD-1 Treatment in Natural Killer/T-Cell Lymphoma
50 Positive Anti-PD-1 Data in Gastric, Esophageal Cancer
51 Increasing the effectiveness of cancer treatments: Anti-PD-L1 immunotherapy
52 Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC
53 Momentum Building for Anti-PD-1/L1 in Breast Ca
54 Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
55 Repurposing Heart Drugs Could Improve Responses to PDL1 Immunotherapy in Cancer Patients
56 Anti-PD-1 Therapy May Induce Better Survival Outcomes Compared With Anti-PD-L1
57 Enhancing the efficacy of anti-PD-L1 immunotherapy for cancer
58 Guideline Backs First-Line Anti-PD-1/L1 Therapy in NSCLC
59 New Clue to Anti-PD-L1 Activity in Breast Cancer?
60 Novel Combo Fails to Move OS Needle in Prostate Cancer
61 TG Therapeutics Initiates Rolling Submission of Biologics License Application to US Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia | Antibodies | News Channels
62 Anti-PD-1 therapy induces durable long-term responses in advanced melanoma
63 PD-L1: A Biomarker With Baggage
64 AXL Inhibitor May Counter Anti-PD-1/L1 Resistance
65 TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
66 First-Line Treatment With Merck's KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)
67 Ohio State Researchers Reveal Promising Cervical Cancer Treatment | Ohio State
68 ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no
69 Anti-PD-1 Maintenance Boosts PFS in Metastatic Bladder Cancer
70 Mechanism underlying cancer cells' immune evasion
71 Tool Measuring PD-1/PD-L1 Interaction May Add Precision to Immunotherapy Response Prediction
72 T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma
73 Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy
74 Anticancer Immunotherapy Response Predicted Using New Imaging Tool
75 FDA approves additional recommended dosage for anti-PD-1 therapy
76 What to Do When Anti–PD-1 Therapy Fails in Patients With Melanoma
77 Immunotherapy Expert Puts Fresh Focus on AEs
78 Immunotherapy Does Not Increase Death Risk in Patients With COVID-19
79 CStone Announces CS1001 (Anti-PD-L1 mAb) Phase III Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Plans to Submit a New Drug Application | Antibodies | News Channels
80 New tool identifies which cancer patients are most likely to benefit from immunotherapy
81 PD1 and Immunotherapy: What You Need to Know
82 Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
83 Region 3: Immune and Cellular Tx, Part I
84 Neoadjuvant Anti-PD-1 Scores in Merkel Cell
85 Durable Responses Observed With PD-1/PD-L1 Combination in Urothelial Carcinoma
86 Greater OS With PD-1 Inhibitors vs PD-L1 Inhibitors for Solid Tumors
87 Anti-PD-1 in Melanoma Effective Regardless of BRAF Status
88 Cis interactions make immune checkpoint blockade more trans-parent
89 Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
90 Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma
91 Dual PD-1/L1 Blockade Shows No Added Benefit in RCC
92 TIGIT Emerging as Target in Clinical Research Across Cancer Settings
93 Pneumonitis From Anti–PD-1/ PD-L1 Therapy
94 Anti-PD-1 Success in Advanced NSCLC Persists
95 Novel Molecule Enhances Immunotherapy Response in CRC, According to Early Data
96 Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
97 Immuno-oncology agents for cancer therapy | Review article
98 First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer
99 FDA approves Keytruda for cutaneous squamous cell carcinoma
100 Esmo 2020 – some backing for Beigene’s unusual combo approach